Changing epidemiology and emerging risk groups for pertussis

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 4, 2006, Pages 451-452

  Galanis, Eleni ^a,b   King, Arlene S ^a   Varughese, Paul ^a   Halperin, Scott Alan ^c  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INACTIVATED VIRUS VACCINE; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; BACTERIUM CULTURE; BORDETELLA PERTUSSIS; DRUG EFFICACY; HIGH RISK POPULATION; HUMAN; IMMUNITY; INCIDENCE; PERTUSSIS; POLYMERASE CHAIN REACTION; SIDE EFFECT; THROAT CULTURE; VACCINATION;

EID: 33644530024     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.050379     Document Type: Article

References (3)

1. Gustafsson L, Hallander HO, Reizenstein E, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
2. Bentsi-Enchill AD, Halperin SA, Scott J, et al. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997;15:301-6.
3. McWha L, MacArthur A, Badiani T, et al. Measuring up: Results from the National Immunization Coverage Survey, 2002. Can Commun Dis Rep 2004;30:37-50.